These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 28419723)

  • 1. Characteristics and outcomes of ALK+ non-small cell lung cancer patients in Korea.
    Lim SH; Yoh KA; Lee JS; Ahn MJ; Kim YJ; Kim SH; Zhang J; Patel D; Swallow E; Kageleiry A; Galebach P; Lee D; Stein K; Degun R; Park K
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e239-e245. PubMed ID: 28419723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.
    Cadranel J; Park K; Arrieta O; Pless M; Bendaly E; Patel D; Sasane M; Nosal A; Swallow E; Galebach P; Kageleiry A; Stein K; Degun R; Zhang J
    Lung Cancer; 2016 Aug; 98():9-14. PubMed ID: 27393500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy.
    Guérin A; Sasane M; Wakelee H; Zhang J; Culver K; Dea K; Nitulescu R; Galebach P; Macalalad AR
    Curr Med Res Opin; 2015 Aug; 31(8):1587-97. PubMed ID: 26029864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
    Duruisseaux M; Besse B; Cadranel J; Pérol M; Mennecier B; Bigay-Game L; Descourt R; Dansin E; Audigier-Valette C; Moreau L; Hureaux J; Veillon R; Otto J; Madroszyk-Flandin A; Cortot A; Guichard F; Boudou-Rouquette P; Langlais A; Missy P; Morin F; Moro-Sibilot D
    Oncotarget; 2017 Mar; 8(13):21903-21917. PubMed ID: 28423535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients.
    Bendaly E; Dalal AA; Culver K; Galebach P; Bocharova I; Foster R; Sasane M; Macalalad AR; Guérin A
    Adv Ther; 2017 Jul; 34(7):1673-1685. PubMed ID: 28578501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
    Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Treatment Patterns, Survival, and Prediction of CNS Progression in ALK-Positive Non-Small-Cell Lung Cancer Patients Treated with First-Line Crizotinib in Latin America Oncology Practices.
    Martín C; Cardona AF; Zatarain-Barrón ZL; Ruiz-Patiño A; Castillo O; Oblitas G; Corrales L; Lupinacci L; Pérez MA; Rojas L; González L; Chirinos L; Ortíz C; Lema M; Vargas C; Puparelli C; Carranza H; Otero J; Arrieta O
    Oncology; 2018; 94(5):297-305. PubMed ID: 29510386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study.
    Bendaly E; Dalal AA; Culver K; Galebach P; Bocharova I; Foster R; Sasane M; Macalalad AR; Guérin A
    Adv Ther; 2017 May; 34(5):1145-1156. PubMed ID: 28405961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer.
    Yoshida T; Oya Y; Tanaka K; Shimizu J; Horio Y; Kuroda H; Sakao Y; Hida T; Yatabe Y
    Lung Cancer; 2016 Jul; 97():43-7. PubMed ID: 27237026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.
    Ou SH; Jänne PA; Bartlett CH; Tang Y; Kim DW; Otterson GA; Crinò L; Selaru P; Cohen DP; Clark JW; Riely GJ
    Ann Oncol; 2014 Feb; 25(2):415-22. PubMed ID: 24478318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic.
    Miloš P; Jana S; Vítězslav K; Monika Š; Leona K; Jaromír R; Renata C; Markéta Č; Andrea B; Juraj K; Michal H; Milada Z; Marek K; Helena Č; Martin S
    Klin Onkol; 2018; 31(3):207-212. PubMed ID: 30441974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.
    Cui S; Zhao Y; Dong L; Gu A; Xiong L; Qian J; Zhang W; Niu Y; Pan F; Jiang L
    Cancer Med; 2016 Jun; 5(6):1013-21. PubMed ID: 26880708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.
    Ock CY; Yoo SH; Keam B; Kim M; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS
    Korean J Intern Med; 2019 Sep; 34(5):1116-1124. PubMed ID: 29950554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.
    Tan DS; Araújo A; Zhang J; Signorovitch J; Zhou ZY; Cai X; Liu G
    J Thorac Oncol; 2016 Sep; 11(9):1550-7. PubMed ID: 27288979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world outcome of crizotinib for anaplastic lymphoma kinase-positive lung cancer: Multicenter retrospective analysis in South Korea.
    Jeon DS; Park CK; Kim SJ; Park CK; Chang YS; Jung CY; Lee SY; Lee SY; Ryu JS; Lee JE; Lee KY; Jang TW; Jang SH; Yoon SH; Lee SH; Choi CM; Kim HR; Kim YJ
    Thorac Cancer; 2024 Feb; 15(6):448-457. PubMed ID: 38171544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of Patients with ALK-positive Non-small Cell Lung Cancer 
and Brain Metastases].
    Lv J; Zhang Q; Qin N; Yang X; Zhang X; Wu Y; Li X; Zhang H; Wang J; Zhang S
    Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):519-24. PubMed ID: 27561801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
    Ito K; Hataji O; Kobayashi H; Fujiwara A; Yoshida M; D'Alessandro-Gabazza CN; Itani H; Tanigawa M; Ikeda T; Fujiwara K; Fujimoto H; Kobayashi T; Gabazza EC; Taguchi O; Yamamoto N
    J Thorac Oncol; 2017 Feb; 12(2):390-396. PubMed ID: 27498387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment.
    Zhou J; Zheng J; Zhang X; Zhao J; Zhu Y; Shen Q; Wang Y; Sun K; Zhang Z; Pan Z; Shen Y; Zhou J
    BMC Cancer; 2018 Jan; 18(1):10. PubMed ID: 29298713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer.
    Hong X; Chen Q; Ding L; Liang Y; Zhou N; Fang W; Chen X; Wu H
    Oncotarget; 2017 Jun; 8(25):41631-41640. PubMed ID: 28427213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.